Skip to content
Screener

King Pharmaceuticals KG Reinsurance Recoverables

Reinsurance Recoverables at other companies

Voya Financial logo
Voya FinancialVOYA
$10.46B-4.7%
Assurant logo
AssurantAIZ
$6.35B-13.4%
MetLife logo
MetLifeMET
$3.09B+2.4%
KG
King PharmaceuticalsKG
$412.12M-20.8%
Primerica logo
PrimericaPRI
$2.44B-9.2%
Primerica logo
PrimericaPRI
$14.97M+2.1%

Other financials

Income statement

See full
Revenue$6.7M+20.1%
Net income-$8.1M-112%
EPS (diluted)-$1.03-107%

Balance sheet

See full
Cash & equivalents$26.3M-43.2%
Total debt$177.0M+0.6%
Total equity$114.0M-24.1%
Total assets$919.6M-20.7%

Cash flow

See full
Operating cash flow-$25.8M-30.0%

Valuation

See full
Market cap$68.85M-74.2%
Enterprise value$219.57M-44.6%
P/E1.4×—
P/S1.6×-30.3×

Profitability

See full
Net margin110.8%—

Returns & leverage

See full
Return on equity37.4%—
Debt / equity1.6×+0.4×

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ReinsuranceRecoverables.

The source filing: King Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →

Filed
Aug 7, 2026, 8:49 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054606

FAQ

What is King Pharmaceuticals's reinsurance recoverables?
King Pharmaceuticals (KG) reported reinsurance recoverables of $412.12M in Q2 2026.
How has King Pharmaceuticals's reinsurance recoverables changed year-over-year?
King Pharmaceuticals's reinsurance recoverables decreased by 20.8% year-over-year, from $520.52M to $412.12M.
What does reinsurance recoverables mean?
Reinsurance Recoverables as reported by Kestrel Group Ltd.

Ask your AI about King Pharmaceuticals's reinsurance recoverables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude